

# Zbigniew Puch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/136816/publications.pdf>

Version: 2024-02-01

10  
papers

344  
citations

1163117

8  
h-index

1281871

11  
g-index

11  
all docs

11  
docs citations

11  
times ranked

558  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>SRGAP1</i> Is a Candidate Gene for Papillary Thyroid Carcinoma Susceptibility. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E973-E980.	3.6	74
2	Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1077-1086.	6.4	71
3	Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi. Thyroid Research, 2010, 3, 9.	1.5	53
4	13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. Thyroid Research, 2009, 2, 8.	1.5	51
5	Rekomendacje Polskich Towarzystw Naukowych –Diagnostyka i leczenie raka tarczycy– Aktualizacja na rok 2018. Endokrynologia Polska, 2018, 69, 34-74.	1.0	32
6	Ciężka stratyfikacja ryzyka w zróżnicowanym raku tarczycy (DTC) – stymulowane stężenie tyreoglobuliny (Tg) w surowicy, przed leczeniem uzupełniającym radiojodem (RAI), najważniejszym czynnikiem ryzyka nawrotu raka u pacjentów w MO. Endokrynologia Polska, 2016, 67, 2-11.	1.0	20
7	Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer. European Journal of Endocrinology, 2015, 173, 873-881.	3.7	13
8	The role of FDG-PET in localization of recurrent lesions of differentiated thyroid cancer (DTC) in patients with asymptomatic hyperthyroglobulinemia in a real clinical practice. European Journal of Endocrinology, 2016, 175, 379-385.	3.7	10
9	Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma. Nuclear Medicine and Molecular Imaging, 2019, 53, 320-327.	1.0	10
10	Wiek zachorowania i płeć jako czynniki modyfikujące związek polimorfizmów zlokalizowanych na chromosomie 9q22 i 14q13 z rakiem brodawkowatym tarczycy. Endokrynologia Polska, 2017, 68, 283-289.	1.0	6